Telix Pharmaceuticals Limited (TLPPF)
OTCMKTS · Delayed Price · Currency is USD
10.25
-0.55 (-5.09%)
Oct 20, 2025, 3:59 PM EDT
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36 million in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23 million, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69 million with 41.49% growth.
Revenue (ttm)
664.23M
Revenue Growth
+55.35%
P/S Ratio
5.63
Revenue / Employee
1.57M
Employees
234
Market Cap
3.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
American Oncology Network | 1.76B |
Veradigm | 588.02M |
Jushi Holdings | 256.36M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
Silence Therapeutics | 27.17M |
Nuo Therapeutics | 1.95M |
Northwest Biotherapeutics | 1.09M |
Telix Pharmaceuticals News
- 4 days ago - TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 5 days ago - Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX - PRNewsWire
- 5 days ago - TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 6 days ago - Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance - Benzinga
- 6 days ago - Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance - Benzinga
- 6 days ago - Telix Pharmaceuticals (TLPPF) Raises Revenue Guidance After Strong Q3 - GuruFocus
- 6 days ago - Telix Pharmaceuticals boosts FY25 guidance after strong Q3 - Seeking Alpha
- 6 days ago - Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded - GlobeNewsWire